Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. (Q37957839)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

main subject

Gram-negative bacteria

0 references

antimicrobial resistance

1 reference

Rui Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Xu-Hong Yu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

16 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

255-268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosmidomycin Resistance in Adenylate Cyclase Deficient (cya) Mutants ofEscherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Biological costs and mechanisms of fosfomycin resistance in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Identification of a novel UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) from Vibrio fischeri that confers high fosfomycin resistance in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin-resistance plasmids determine an intracellular modification of fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Novel Fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

High frequency of mutator strains among human uropathogenic Escherichia coli isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Bactericidal activity of tinidazole. An in vitro comparison of the effects of tinidazole and metronidazole against Bacteroides fragilis and other Anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Detection of hypermutable Escherichia coli strains in a collection of clinical isolates by the fosfomycin-rifampin disk method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/Co-trimoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Sulfadiazine-Trimethoprim Combination in the Treatment of Urinary Tract Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin in the treatment of gynecological infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin in acute bronchopneumopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Bacteriological evaluation of fosfomycin in clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Treatment of chronic suppurated otitis with fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Effect of Fosfomycin on the Fecal Microflora of Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

[Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?]

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Antibiotic resistance transformation in community-acquired urinary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Why fosfomycin trometamol as first line therapy for uncomplicated UTI?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

A theoretical and experimental analysis of bacterial growth in the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Introducing fosfomycin for surgical prophylaxis--emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Effect of enzyme I of the bacterial phosphoenolpyruvate : sugar phosphotransferase system (PTS) on virulence in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of an Italian multicenter survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Extracellular concentrations of fosfomycin in lung tissue of septic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Mutation frequencies and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Mutator bacteria as a risk factor in treatment of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Minimizing potential resistance: a population dynamics view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR466

Zelkovamycin, a new cyclic peptide antibiotic from Streptomyces sp. K96-0670. II. Structure elucidation

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.52.34

Identifiers

DOI

10.1093/JAC/DKR466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22096042%20AND%20SRC:MED&resulttype=core&format=json

release_73rzfglve5c3fe6o7ze5cpehmi

16 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/73rzfglve5c3fe6o7ze5cpehmi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference